Peer-influenced content. Sources you trust. No registration required. This is HCN.

Psychiatrist.comSolriamfetol for Attention-Deficit/Hyperactivity Disorder in Adults: A Double-Blind Placebo-Controlled Pilot Study

Solriamfetol: A Potential New Treatment for Adult ADHD

A recent pilot study has explored the potential of solriamfetol as a treatment for adults with attention-deficit/hyperactivity disorder (ADHD). The study aimed to determine the drug’s efficacy and tolerability.

HCN Medical Memo
The results of this pilot study suggest that solriamfetol could be a promising new treatment option for adults with ADHD. Healthcare professionals should consider this when exploring treatment options for patients who may not tolerate or adequately respond to currently available treatments.

Study Design

  • The study was a remotely conducted, randomized, double-blind, placebo-controlled, 6-week dose-optimization trial.
  • Sixty adults diagnosed with DSM-5 ADHD participated from August 2021 through January 2023.
  • Participants were administered either 75 mg or 150 mg of solriamfetol.

This is one of the first studies to explore the use of solriamfetol, a drug typically used to treat sleep disorders, as a potential treatment for ADHD.

Key Findings

  • Solriamfetol was well tolerated with no significant effect on mean heart rate, systolic blood pressure, or diastolic blood pressure.
  • Adverse events were not significantly different from those on placebo.
  • By the study endpoint, a greater proportion of individuals in the treatment group met the a priori–defined treatment response.
  • Those treated with solriamfetol also had greater improvement in total AISRS scores by week 3 through week 6.

More on ADHD

The Healthcare Communications Network is owned and operated by IQVIA Inc.

Click below to leave this site and continue to IQVIA’s Privacy Choices form